Clinical Trials
18 trialsNCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT07216105 2026-04-07
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT00957411 2025-11-24
CETUXICOL
Institut Curie
Phase 2 Completed
NCT04956640 2025-09-25
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Recruiting
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT00997009 2023-11-14
MITO CERV 2
National Cancer Institute, Naples
Phase 2 Unknown
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT00499031 2015-01-13
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00104910 2014-12-31
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
GOG Foundation
Phase 1 Completed
NCT00101192 2014-03-17
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00086892 2014-02-14
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00392769 2012-09-06
Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00518193 2011-06-30
ERBUS
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT00292955 2011-05-30
Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma
University of Virginia
Phase 2 Unknown
NCT00082212 2010-04-09
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Eli Lilly and Company
Phase 2 Terminated
NCT00063401 2010-04-08
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Eli Lilly and Company
Phase 2 Completed